Human Papillomavirus (HPV) E7 protein (49-57) is the H-2d-restricted human papillomavirus (HPV) E749-57 epitope (short peptide spanning the 49th to 57th amino acid residues in the E7 protein).
Human Papillomavirus (HPV) E7 protein 49-57 is a synthetic peptide fragment derived from the E7 oncoprotein of HPV, specifically encompassing amino acids 49 to 57. This sequence is recognized for its pivotal role in viral-host interactions, particularly in the context of HPV-induced cellular transformation and immune recognition. The E7 protein is a key factor in the oncogenic potential of high-risk HPV types, making its peptide fragments highly relevant for studies in molecular virology, immunology, and cancer research. The 49-57 epitope is notable for its immunogenic properties, frequently utilized in research settings to investigate cellular immune responses and antigen processing pathways associated with HPV infection.
Immunological assays: The E7 49-57 peptide is widely employed as a defined epitope in immunological studies, particularly those focused on T cell recognition and activation. Researchers use this peptide to stimulate cytotoxic T lymphocytes (CTLs) in vitro, enabling the evaluation of antigen-specific immune responses. Such assays facilitate the analysis of immune surveillance mechanisms against HPV-infected or transformed cells, providing insights into host-pathogen interactions and the development of immune-based detection platforms.
Epitope mapping: The defined sequence of the E7 49-57 region serves as a reference standard for mapping T cell epitopes within the HPV E7 protein. By incorporating this peptide into mapping experiments, scientists can delineate the minimal recognition motifs necessary for major histocompatibility complex (MHC) binding and T cell receptor engagement. This approach is instrumental in characterizing immunodominant regions and advancing our understanding of antigen presentation in the context of HPV infection.
Antigen processing studies: The peptide is frequently utilized to investigate the intracellular pathways responsible for antigen processing and presentation. By introducing the E7 49-57 fragment into various cell types, researchers can dissect the mechanisms by which viral peptides are generated, loaded onto MHC molecules, and displayed on the cell surface. Such studies are essential for elucidating the molecular basis of immune recognition and for identifying potential bottlenecks in the presentation of viral antigens.
Peptide-based vaccine research: As an immunogenic epitope, the E7 49-57 peptide is a valuable tool in preclinical research aimed at developing peptide-based vaccines targeting HPV-associated malignancies. Its use allows for the assessment of peptide immunogenicity, optimization of vaccine formulations, and evaluation of adjuvant strategies designed to enhance antigen-specific T cell responses. These investigations contribute to the rational design of next-generation immunotherapeutic approaches.
Quality control and assay development: The E7 49-57 peptide is also applied as a positive control or standard in the development and validation of immunoassays, such as enzyme-linked immunospot (ELISpot) and flow cytometry-based assays. By providing a consistent and well-characterized target, it ensures assay reliability and reproducibility across experimental platforms, supporting the robust measurement of antigen-specific cellular responses in research settings.
3. Implications of ligand-receptor binding kinetics on GLP-1R signalling
4. Immune-awakening Saccharomyces-inspired nanocarrier for oral target delivery to lymph and tumors
5. Emerging applications of nanotechnology for diagnosis and therapy of disease: a review
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More